115 research outputs found
A Study of Affective Objectives in the Teaching of Chemistry
An examination of certain proposed affective objectives of Chemistry education has been carried out, particularly with the intention of determining whether these objectives are being attained by Scottish pupils following S. C. E. courses in Chemistry at Secondary Schools. A critical survey of Attitude concept and theory has been made, together with an account of measurement procedures which have been devised for attitude assessment and which have been reported in the literature. Results of research have also been reported, particularly in the area of the affective component of attitude to science education. Current opinions on the formulation of desirable affective objectives in education have been included, and critical comment on those proposed for current science syllabuses in Scotland has been made. Questionnaires have been devised employing various attitude measurement techniques in an attempt to measure the attitudes of both pupils and teachers to education in Chemistry. A pre-test has been done in a small number of schools and, after modification, the questionnaires have been circulated to over thirty schools throughout the country. Twenty eight schools cooperated and over thirteen hundred pupils and one hundred science teachers completed questionnaires. A computer programme was prepared to process the data which emerged and to apply statistical analysis procedures. The results from various categories of pupils have been compared and findings have been reported. Pupils who had not included science subjects in their course were used as control groups. A comparison of results obtained by three distinct methods of analysing the data has been carried out, and an attempt to demonstrate that one of these is clearly more appropriate in assessing attitudes has been made. Results from individual schools have been discussed, and a detailed survey of five schools has been made in an attempt to relate the results from pupils in these schools to the attitudes of their teachers and to their school environment. Suggestions for further work in this field have been proposed which are considered not only to be relevant to the teaching of Chemistry, but essential if Chemistry is to make its fullest contribution to the educational process
Design of free-space couplers for suspended triangular nano-beam waveguides
Photonic waveguides (WGs) with triangular cross section are being investigated for material systems such as diamond, glasses and gallium nitride, which lack easy options to create conventional rectangular nanophotonic waveguides. The design rules for optical elements in these triangular WGs, such as couplers and gratings, are not well established. Here we present simulations of elements designed to couple light into, and out of, triangular WGs from the vertical direction, which can be implemented with current angled-etch fabrication technology. The devices demonstrate coupling efficiencies approaching 50% for light focused from a high numerical aperture objective. The implementation of such couplers will enable fast and efficient testing of closely spaced integrated circuit components
European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of GuillainâBarrĂ© syndrome
GuillainâBarrĂ© syndrome (GBS) is an acute polyradiculoneuropathy. Symptoms may vary greatly in presentation and severity. Besides weakness and sensory disturbances, patients may have cranial nerve involvement, respiratory insufficiency, autonomic dysfunction and pain. To develop an evidence-based guideline for the diagnosis and treatment of GBS, using Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology, a Task Force (TF) of the European Academy of Neurology (EAN) and the Peripheral Nerve Society (PNS) constructed 14 Population/Intervention/Comparison/Outcome questions (PICOs) covering diagnosis, treatment and prognosis of GBS, which guided the literature search. Data were extracted and summarised in GRADE Summaries of Findings (for treatment PICOs) or Evidence Tables (for diagnostic and prognostic PICOs). Statements were prepared according to GRADE Evidence-to-Decision (EtD) frameworks. For the six intervention PICOs, evidence-based recommendations are made. For other PICOs, good practice points (GPPs) are formulated. For diagnosis, the principal GPPs are: GBS is more likely if there is a history of recent diarrhoea or respiratory infection; CSF examination is valuable, particularly when the diagnosis is less certain; electrodiagnostic testing is advised to support the diagnosis; testing for anti-ganglioside antibodies is of limited clinical value in most patients with typical motor-sensory GBS, but anti-GQ1b antibody testing should be considered when Miller Fisher syndrome (MFS) is suspected; nodalâparanodal antibodies should be tested when autoimmune nodopathy is suspected; MRI or ultrasound imaging should be considered in atypical cases; and changing the diagnosis to acute-onset chronic inflammatory demyelinating polyradiculoneuropathy (A-CIDP) should be considered if progression continues after 8 weeks from onset, which occurs in around 5% of patients initially diagnosed with GBS. For treatment, the TF recommends intravenous immunoglobulin (IVIg) 0.4 g/kg for 5 days, in patients within 2 weeks (GPP also within 2â4 weeks) after onset of weakness if unable to walk unaided, or a course of plasma exchange (PE) 12â15 L in four to five exchanges over 1â2 weeks, in patients within 4 weeks after onset of weakness if unable to walk unaided. The TF recommends against a second IVIg course in GBS patients with a poor prognosis; recommends against using oral corticosteroids, and weakly recommends against using IV corticosteroids; does not recommend PE followed immediately by IVIg; weakly recommends gabapentinoids, tricyclic antidepressants or carbamazepine for treatment of pain; does not recommend a specific treatment for fatigue. To estimate the prognosis of individual patients, the TF advises using the modified Erasmus GBS outcome score (mEGOS) to assess outcome, and the modified Erasmus GBS Respiratory Insufficiency Score (mEGRIS) to assess the risk of requiring artificial ventilation. Based on the PICOs, available literature and additional discussions, we provide flow charts to assist making clinical decisions on diagnosis, treatment and the need for intensive care unit admission.</p
European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of GuillainâBarrĂ© syndrome
GuillainâBarrĂ© syndrome (GBS) is an acute polyradiculoneuropathy. Symptoms may vary greatly in presentation and severity. Besides weakness and sensory disturbances, patients may have cranial nerve involvement, respiratory insufficiency, autonomic dysfunction and pain. To develop an evidence-based guideline for the diagnosis and treatment of GBS, using Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology a Task Force (TF) of the European Academy of Neurology (EAN) and the Peripheral Nerve Society (PNS) constructed 14 Population/Intervention/Comparison/Outcome questions (PICOs) covering diagnosis, treatment and prognosis of GBS, which guided the literature search. Data were extracted and summarised in GRADE Summaries of Findings (for treatment PICOs) or Evidence Tables (for diagnostic and prognostic PICOs). Statements were prepared according to GRADE Evidence-to-Decision (EtD) frameworks. For the six intervention PICOs, evidence-based recommendations are made. For other PICOs, good practice points (GPPs) are formulated. For diagnosis, the principal GPPs are: GBS is more likely if there is a history of recent diarrhoea or respiratory infection; CSF examination is valuable, particularly when the diagnosis is less certain; electrodiagnostic testing is advised to support the diagnosis; testing for anti-ganglioside antibodies is of limited clinical value in most patients with typical motor-sensory GBS, but anti-GQ1b antibody testing should be considered when Miller Fisher syndrome (MFS) is suspected; nodalâparanodal antibodies should be tested when autoimmune nodopathy is suspected; MRI or ultrasound imaging should be considered in atypical cases; and changing the diagnosis to acute-onset chronic inflammatory demyelinating polyradiculoneuropathy (A-CIDP) should be considered if progression continues after 8 weeks from onset, which occurs in around 5% of patients initially diagnosed with GBS. For treatment, the TF recommends intravenous immunoglobulin (IVIg) 0.4 g/kg for 5 days, in patients within 2 weeks (GPP also within 2â4 weeks) after onset of weakness if unable to walk unaided, or a course of plasma exchange (PE) 12â15 L in four to five exchanges over 1â2 weeks, in patients within 4 weeks after onset of weakness if unable to walk unaided. The TF recommends against a second IVIg course in GBS patients with a poor prognosis; recommends against using oral corticosteroids, and weakly recommends against using IV corticosteroids; does not recommend PE followed immediately by IVIg; weakly recommends gabapentinoids, tricyclic antidepressants or carbamazepine for treatment of pain; does not recommend a specific treatment for fatigue. To estimate the prognosis of individual patients, the TF advises using the modified Erasmus GBS outcome score (mEGOS) to assess outcome, and the modified Erasmus GBS Respiratory Insufficiency Score (mEGRIS) to assess the risk of requiring artificial ventilation. Based on the PICOs, available literature and additional discussions, we provide flow charts to assist making clinical decisions on diagnosis, treatment and the need for intensive care unit admission.</p
Impact of nonoptimal intakes of saturated, polyunsaturated, and trans fat on global burdens of coronary heart disease
Background: Saturated fat (SFA), Ïâ6 (nâ6) polyunsaturated fat (PUFA), and trans fat (TFA) influence risk of coronary heart disease (CHD), but attributable CHD mortalities by country, age, sex, and time are unclear. Methods and Results: National intakes of SFA, nâ6 PUFA, and TFA were estimated using a Bayesian hierarchical model based on countryâspecific dietary surveys; food availability data; and, for TFA, industry reports on fats/oils and packaged foods. Etiologic effects of dietary fats on CHD mortality were derived from metaâanalyses of prospective cohorts and CHD mortality rates from the 2010 Global Burden of Diseases study. Absolute and proportional attributable CHD mortality were computed using a comparative risk assessment framework. In 2010, nonoptimal intakes of nâ6 PUFA, SFA, and TFA were estimated to result in 711 800 (95% uncertainty interval [UI] 680 700â745 000), 250 900 (95% UI 236 900â265 800), and 537 200 (95% UI 517 600â557 000) CHD deaths per year worldwide, accounting for 10.3% (95% UI 9.9%â10.6%), 3.6%, (95% UI 3.5%â3.6%) and 7.7% (95% UI 7.6%â7.9%) of global CHD mortality. Tropical oilâconsuming countries were estimated to have the highest proportional nâ6 PUFAâ and SFAâattributable CHD mortality, whereas Egypt, Pakistan, and Canada were estimated to have the highest proportional TFAâattributable CHD mortality. From 1990 to 2010 globally, the estimated proportional CHD mortality decreased by 9% for insufficient nâ6 PUFA and by 21% for higher SFA, whereas it increased by 4% for higher TFA, with the latter driven by increases in lowâ and middleâincome countries. Conclusions: Nonoptimal intakes of nâ6 PUFA, TFA, and SFA each contribute to significant estimated CHD mortality, with important heterogeneity across countries that informs nationâspecific clinical, public health, and policy priorities.peer-reviewe
Accelerated surgery versus standard care in hip fracture (HIP ATTACK): an international, randomised, controlled trial
Telomerecat: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data.
Telomere length is a risk factor in disease and the dynamics of telomere length are crucial to our understanding of cell replication and vitality. The proliferation of whole genome sequencing represents an unprecedented opportunity to glean new insights into telomere biology on a previously unimaginable scale. To this end, a number of approaches for estimating telomere length from whole-genome sequencing data have been proposed. Here we present Telomerecat, a novel approach to the estimation of telomere length. Previous methods have been dependent on the number of telomeres present in a cell being known, which may be problematic when analysing aneuploid cancer data and non-human samples. Telomerecat is designed to be agnostic to the number of telomeres present, making it suited for the purpose of estimating telomere length in cancer studies. Telomerecat also accounts for interstitial telomeric reads and presents a novel approach to dealing with sequencing errors. We show that Telomerecat performs well at telomere length estimation when compared to leading experimental and computational methods. Furthermore, we show that it detects expected patterns in longitudinal data, repeated measurements, and cross-species comparisons. We also apply the method to a cancer cell data, uncovering an interesting relationship with the underlying telomerase genotype
Observer blind randomised controlled trial of a tailored home exercise programme versus usual care in people with stable inflammatory immune mediated neuropathy
Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barre syndrome
- âŠ